Everything below concerns synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
They are an important item in sadya, a vegetarian feast prepared during festive occasions in Kerala. The chips are typically labeled "plantain chips" when they are made of green plantains that taste starchy, like potato chips. In Tamil Nadu, a thin variety made from green plantains is used to make chips seasoned with salt, chili powder and asafoetida. In the western/central Indian language Marathi, the plantain is called rajeli kela (figuratively meaning "king-sized" banana), and is often used to make fried chips.
== Further reading == Adams, Jad (2004) Hideous absinthe: a history of the devil in a bottle, London: I.B. Tauris. ISBN 1860649203 Arnold, Wilfred Niels (June 1989). "Absinthe". Scientific American. 260 (6): 112–117. Bibcode:1989SciAm.260f.112A. doi:10.1038/scientificamerican0689-112. PMID 2658044. S2CID 215053033. Retrieved 18 September 2010. Blumer, D. (2002). "The Illness of Vincent van Gogh". American Journal of Psychiatry. 159 (4): 519–526. doi:10.1176/appi.ajp.159.4.519. PMID 11925286. S2CID 43106568. Conrad, Barnaby (1996). Absinthe: History in a Bottle. San Francisco: Chronicle Books. ISBN 978-0811816502. Crowley, Aleister (1918). "Absinthe: The Green Goddess" (PDF). The International. XII (2). Archived from the original (PDF) on 18 September 2020. Retrieved 5 March 2016. Eadie, MJ (2009). "Absinthe, epileptic seizures and Valentin Magnan". The Journal of the Royal College of Physicians of Edinburgh. 39 (1): 73–78. doi:10.1177/1478271520093901011. PMID 19831287. Guthrie, R. Winston (2010). A Taste for Absinthe. New York: Clarkson Potter. p. 176. ISBN 978-0307587534. Archived from the original on 28 February 2019. Retrieved 26 September 2012. Huisman, M.; Brug, J.; MacKenbach, J. (2007). "Absinthe is its history relevant for current public health?". International Journal of Epidemiology. 36 (4): 738–744. doi:10.1093/ije/dym068. hdl:1765/36056. PMID 17982755. Lachenmeier, Dirk W.; Nathan-Maister, David; Breaux, Theodore A.; Sohnius, Eva-Maria; Schoeberl, Kerstin; Kuballa, Thomas (2008).
After an initial or primary fermentation, beer is conditioned, matured or aged, in one of several ways, which can take from 2 to 4 weeks, several months, or several years, depending on the brewer's intention for the beer. The beer is usually transferred into a second container, so that it is no longer exposed to the dead yeast and other debris (also known as "trub") that have settled to the bottom of the primary fermenter. This prevents the formation of unwanted flavours and harmful compounds such as acetaldehyde.
== Reception == Kevin Knox, who was in charge of doughnuts food quality at Starbucks from 1987 to 1993, recalled on his blog in 2010 how George Howell, coffee veteran and founder of the Cup of Excellence, had been appalled at the dark roasted beans that Starbucks was selling in 1990. Talking to The New York Times in 2008, Howell stated his opinion that the dark roast used by Starbucks does not deepen the flavor of coffee, but instead can destroy purported nuances of flavor. The March 2007 issue of Consumer Reports compared American fast-food chain coffees and ranked Starbucks behind McDonald's Premium Roast in the middle of a coffee war. The magazine called Starbucks coffee "strong, but burnt and bitter enough to make your eyes water instead of open". As reported by Time in 2010, third wave coffee proponents generally criticize Starbucks for over-roasting beans. As a result, Starbucks retrained its baristas and changed its roasting methods in 2010 to "standardize quality over quantity". The Atlantic reported that this push for higher-quality coffee slowed down orders but stated that "[they] move their product pretty quickly, and with surprising accuracy". Forbes corroborated this trade off between efficiency and quality at Starbucks. In 2018, Business Insider conducted a test of Starbucks coffee judged by 100 coffee experts. It concluded that although staples of the menu were "too sugary", coffee quality materially improved with particularly strong showings in the firm's iced coffee and nitro cold brew coffee offerings.
Azurin is a small, periplasmic, bacterial blue copper protein found in Pseudomonas, Bordetella, or Alcaligenes bacteria. Azurin moderates single-electron transfer between enzymes associated with the cytochrome chain by undergoing oxidation-reduction between Cu(I) and Cu(II). Each monomer of an azurin tetramer has a molecular weight of approximately 14kDa, contains a single copper atom, is intensively blue, and has a fluorescence emission band centered at 308 nm. Azurins and pseudoazurins participate in the denitrification processes in bacteria., including the gram-negative bacteria Pseudomonas aeruginosa, by interacting with cytochrome c551. Azurin from P aeruginosa is a type I blue copper protein (cupredoxin), while cytochrome c551 (9 kDa) is a haem-containing cytochrome. Azurin possesses a relatively large hydrophobic patch close to the active site, and two residues in this hydrophobic patch, Met-44 and Met-64, are believed to be involved in its interaction with the redox partners cytochrome c551 and nitrite reductase. Although unrelated to its electron-transfer property, azurin has been found to have anticancer properties through its interaction with tumor-suppressor protein p53.
Sources: en.wikipedia.org
=== Operation Edzell === An undercover policewoman from the Metropolitan Police Special Operations Group (SO10) contacted Stagg, posing as a friend of a woman with whom he used to be in contact via a lonely hearts' column. Over five months, she attempted to obtain information from him by feigning a romantic interest, meeting him, speaking to him on the telephone and exchanging letters containing sexual fantasies. During a meeting in Hyde Park, they spoke about the Nickell homicide; he later said that he had only played along with the topic because he wanted to pursue the romance. Profiler Paul Britton later said that he disagreed with use of the fantasy-filled letters and knew nothing of them until after they had been sent. The undercover officer won Stagg's confidence and drew out fantasies from him that psychologist Paul Britton interpreted as "violent", but he did not admit to the killing. Police released a taped conversation between the police officer and him, in which she claimed to enjoy hurting people, to which he mumbled, "Please explain, as I live a quiet life. If I have disappointed you, please don't dump me. Nothing like this has happened to me before". When she went on to say, "If only you had done the Wimbledon Common murder, if only you had killed her, it would be all right", he replied, "I'm terribly sorry, but I haven't". Stagg was nevertheless arrested and charged on the basis of claims that he had described aspects of the murder scene that only the killer would have known.
=== Somatic recombination === In neurons of the human brain, somatic recombination occurs frequently in the gene that encodes APP. Neurons from individuals with sporadic Alzheimer's disease show greater APP gene diversity due to somatic recombination than neurons from healthy individuals.
On 18 December 2008, at the Old Bailey, Napper pleaded guilty to the manslaughter of Rachel Nickell on the grounds of diminished responsibility. Mr Justice Griffith Williams said that Napper would be detained indefinitely at Broadmoor because he was "a very dangerous man".
Before refilling with the same solution, the syringe needle should be externally rinsed and dried with lint-free paper, without the need for an internal wash. However, when switching to a different reagent or concentration, the syringe must be thoroughly washed, flushed with ethanol or methanol, and carefully dried under vacuum-using a ThermoVac for VP-ITC or the integrated vacuum systems in other models. The sample cell should be emptied using the loading syringe and rinsed multiple times with water.
The LE cell was discovered in bone marrow in 1948 by Hargraves et al. In 1957 Holborow et al. first demonstrated ANA using indirect immunofluorescence. This was the first indication that processes affecting the cell nucleus were responsible for SLE. In 1959 it was discovered that serum from individuals with SLE contained antibodies that precipitated with saline extracts of nuclei, known as extractable nuclear antigens (ENAs). This led to the characterisation of ENA antigens and their respective antibodies. Thus, anti-Sm and anti-RNP antibodies were discovered in 1966 and 1971, respectively. In the 1970s, the anti-Ro/anti-SS-A and anti-La/anti-SS-B antibodies were discovered. The Scl-70 antibody was known to be a specific antibody to scleroderma in 1979, however the antigen (topoisomerase-I) was not characterised until 1986. The Jo-1 antigen and antibody were characterised in 1980.
Sources: en.wikipedia.org
It is said that a person, once he has drunk umm nyolokh, will return to giraffe again and again. Humr, being Mahdists, are strict abstainers [from alcohol] and a Humrawi is never drunk (sakran) on liquor or beer. But he uses this word to describe the effects which umm nyolokh has upon him. Cunnison's remarkable account of an apparently psychoactive mammal found its way from a somewhat obscure scientific paper into more mainstream literature through a conversation between W. James of the Institute of Social and Cultural Anthropology at the University of Oxford and specialist on the use of hallucinogens and intoxicants in society, and R. Rudgley, who discussed it in a book on psychoactive drugs for general readers. He speculated that a hallucinogenic compound, dimethyltryptamine (DMT), of the Giraffa (giraffe) liver might account for benevolent claims of intoxicating beverages (and potentially herbs), such as a beverage (African: umm nyolokh) used by the Arab people of Sudan like a potion. Cunnison wrote in 1958 that found it hard to believe in the literal truth of the Humr's assertion that the drink was intoxicating:
=== Type II diabetes === Diabetes mellitus type 2 is a common disease that causes reduced insulin secretion and increased insulin resistance in the periphery. It results in increased blood glucose levels, or hyperglycemia, which can be fatal if untreated. Since Wnt signaling is involved in insulin sensitivity, malfunctioning of its pathway could be involved. Overexpression of Wnt5b, for instance, may increase susceptibility due to its role in adipogenesis, since obesity and type II diabetes have high comorbidity. Wnt signaling is a strong activator of mitochondrial biogenesis. This leads to increased production of reactive oxygen species (ROS) known to cause DNA and cellular damage. This ROS-induced damage is significant because it can cause acute hepatic insulin resistance, or injury-induced insulin resistance. Mutations in Wnt signaling-associated transcription factors, such as TCF7L2, are linked to increased susceptibility.
=== Evacuation of Kabul === In August 2021, elements of the 82nd Airborne Division, particularly the Immediate Response Force, deployed to Afghanistan to secure the evacuation of American diplomats and Afghan Special Immigrant Visa applicants as the Taliban seized land and converged on Kabul. Throughout Operation Allies Refuge, the 82nd Airborne Division served as the Operational Command, Task Force 82. Operation Allies Refuge, led by Major General Chris Donahue, was a combined and joint NATO command post composed of forces representing NATO allied Nations, 1st Brigade Combat Team "Devil", aviation capabilities from the 82nd Combat Aviation Brigade "Pegasus", medical capabilities from the 44th Medical Brigade, riot control capabilities from the 16th Military Police Brigade, 24th Marine Expeditionary Unit, and the 3rd Expeditionary Sustainment Command who oversaw sustainment in the joint operational area from a command post in Kuwait.
Microsomal prostaglandin E synthase-1 (mPGES-1) or Prostaglandin E synthase is an enzyme that in humans is encoded by the PTGES gene. The protein encoded by this gene is a glutathione-dependent prostaglandin E synthase. The expression of this gene has been shown to be induced by proinflammatory cytokine interleukin 1 beta (IL1B). Its expression can also be induced by tumor suppressor protein TP53, and may be involved in TP53-induced apoptosis. Knockout studies in mice suggest that this gene may contribute to the pathogenesis of collagen-induced arthritis and mediate acute pain during inflammatory responses. It is inhibited by crisdesalazine (AAD-2004; GedaCure).
The HIV-1 PR precursor catalyzes its own production by facilitating its cleavage from the Gag-Pol polyprotein in a mechanism known as auto-processing. Auto-processing of HIV-1 PR is characterized by two sequential steps: (1) the intramolecular cleavage of the N-terminus at the p6pol-protease cleavage site, which serves to finalize PR processing and increase enzymatic activity with the newly formed PR-reverse transcriptase intermediate, and (2) the intermolecular cleavage of the C-terminus at the protease-reverse transcriptase cleavage site, leading to the assembly of two PR subunits into mature dimers. Dimerization of the two subunits allows for fully functional, combined active site, characterized by two Asp25 catalytic residues (one from each monomer), to form.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.